SRRA · Sierra Oncology
Acquired Company
GSK acquired Sierra Oncology on 7/1/2022 for $55 per share in cash, representing an approximate total equity value of $1.9 billion.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$54.99
Open
$54.99
Volume
N/A
Day Range
$54.99 - $54.99
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
N/A
Institutional Own.
N/A
Qtr Updated
Sep 30th 2024
